Navigation Links
Hooper Holmes Announces Third Quarter Earnings Release Date and Conference Call Information
Date:11/3/2008

million telephone interviews.

This press release contains "forward-looking" statements, as such term is defined in the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on the Company's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions. Among the important factors that could cause actual results to differ materially from those expressed in, or implied by, these forward-looking statements are our ability to successfully implement our business strategy; uncertainty as to our working capital requirements over the next 12 to 24 months; our ability to maintain compliance with the financial covenants in our credit facility; our expectations regarding our operating cash flows; and the rate of life insurance application activity. Additional information about these and other factors that could affect the Company's business is set forth in the Company's annual report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission on March 17, 2008. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this press release to reflect the occurrence of unanticipated events, except as required by law.


'/>"/>
SOURCE Hooper Holmes
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Hooper Holmes Heritage Labs Division to Manufacture Biospecimen Kits for the National Childrens Study
2. Hooper Holmes Names Richard Whitbeck President of Portamedic Division
3. Hooper Holmes Announces Sale of Claims Evaluation Division
4. Hooper Holmes Announces First Quarter 2008 Results
5. Hooper Holmes Names Roy Bubbs President and CEO, Benjamin Currier Continues as Chairman
6. Hooper Holmes Announces Fourth Quarter Earnings Release Date and Conference Call Information
7. Hooper Holmes to Provide Business Update
8. Hooper Holmes Updates Guidance
9. Hooper Holmes Marks 50,000 Health and Wellness Screenings
10. Hooper Holmes Announces Third Quarter 2007 Results
11. Hooper Holmes Appoints Leslie Hudson, PhD, to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)PEMBROKE, Bermuda, Dec. 4 Allied World Assurance,Company Holdings, Ltd (NYSE: AWH ) today announced that Scott Carmilani,President and Chief Executive Officer, and Jack Sennott, Executive Vice,Pres
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
(Date:12/4/2009)MADISON HEIGHTS, Mich., Dec. 4 The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Allergan, Inc. (NYSE: AGN ) as its February 2010 "Stock to Stud
(Date:12/4/2009)WASHINGTON, Dec. 4 While Congress debates whether health care reform would control health care costs, Leapfrog,s purchaser members point to 45 hospitals that lead through example -- delivering the be
Breaking Medicine News(10 mins):Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Allied World to Present at the 2009 Goldman Sachs U.S. Financial Services Conference 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2Health News:BetterInvesting Magazine Releases February Stock to Study and Undervalued Stock Choicesfor Investors' Informational and Educational Use 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 2Health News:The Leapfrog Group Releases Its 2009 Top Hospitals List 3
...vider of SOA based data profiling, In-Stream profi...ounces today that it has become a partner in the M...ft Corp. and other key industry partners working t... Chicago, IL (PRWEB) December 16, 2008 -- AMB, a ...
...e Full Support for Clinical Activities , , RO...NMD ), a clinical-stage pharmaceutical company ann...s on its most promising near-term product candidat...calls for acceleration of the Company,s 2009 clini...
...alads over French fries? According to a new study ...choose from a large variety of menu items are more...oose from shorter lists. , In a study that looked...y Liu (UCLA) examined the way consumers justify th...
...chers from Yale University School of Medicine comp...ication to standard white light colonoscopy in dif...lonoscopy and found that NBI was not more accurate... tool. Once this learning curve was achieved, NBI ...
...sparency , , PITTSBURGH, Dec. 15 Highmark B...h online physician quality information in an effor...sions. , , "Today, more people have greater ...d quality performance management. "Publicly report...
...n killer disease, scientists say , , MONDA...y a particular gene may provide a new target for t... , Experiments at the Mayo Clinic College of Medi...eviously linked to excessive growth of pancreatic ...
Other Medicine News:Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 2Health News:AMB New Generation Data Empowerment Joins Mainframe Migration Alliance 3Health News:EntreMed Focuses on Development of ENMD-2076 2Health News:EntreMed Focuses on Development of ENMD-2076 3Health News:EntreMed Focuses on Development of ENMD-2076 4Health News:EntreMed Focuses on Development of ENMD-2076 5Health News:The virtue of variety: More options can lead to healthier choices 2Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 2Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 3Health News:Narrow-band imaging comparable to white light colonoscopy in differentiating colorectal polyps 4Health News:Highmark Blue Cross Blue Shield Provides Online Physician Quality Information to Members 2Health News:Pancreatic Cancer May Have a New Foe 2
(Date:12/4/2009)BILLERICA, Mass., Dec. 4 Axsun Technologies, Inc., a wholly-owned subsidiary of Volcano Corporation (Nasdaq: VOLC ), today announced the initial development and successful testing of a novel integra
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
Breaking Medicine Technology:Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 2Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 3Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 4Axsun Technologies, A Wholly-Owned Subsidiary of Volcano Corporation, Announces Breakthrough Integrated Light Source Architecture for Optical Coherence Tomography (OCT) Imaging 5Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Medizone International Inc Has Filed for Patent Protection for Its AsepticSure 28TM 29 Hospital Sterilization System 51452 1Medizone International Inc Has Filed for Patent Protection for Its AsepticSure 28TM 29 Hospital Sterilization System 51452 2Instrumentation Laboratory to Announce Passion 26 Results Award Winners 12987 1Instrumentation Laboratory to Announce Passion 26 Results Award Winners 12987 2Instrumentation Laboratory to Announce Passion 26 Results Award Winners 12987 3Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 1Bathtub Accidents Injure 43 000 U S Kids Each Year 51446 2
...iread(R) versus Clevudine+Viread(R) in 150 pa... July 8 The French National,Agency for Research o...t of,Pharmasset, Inc. (Nasdaq: VRUS ) and Gilead ...first head-to-head study of clevudine and Viread(R...arately, versus their,combination, for the treatme...
...98 and ANA773 Acting via Independent but ... Conference Call Today at 2:00 PM PDT, SAN DIE...ANDS ) announced today that it is resuming clinica... mechanism for the,treatment of chronic hepatitis ...he results of completed 13-week GLP animal toxicol...
Other Medicine Technology:Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 2Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 3Pharmasset Announces Initiation of Combination Study of Clevudine and Viread(R) for HBV by French National Agency for Research on AIDS and Viral Hepatitis (ANRS) 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 2Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 3Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 4Anadys Pharmaceuticals Resumes Clinical Investigation of TLR7 Mechanism in HCV 5
Fibrinogen Control
MONO Mononucleosis Rapid Test Device
...Z Flu A+B test is a rapid chromatographic immunoas...fluenza A and B viral antigens from nasopharyngeal...patients. The Directigen EZ Flu A+B test is a diff...ens can be distinguished from influenza B viral an...
..., the Jarvik 2000 pump is about the size of a C ba...ect-current motor, a rotor supported by two cerami...nning titanium impeller that pumps blood from the ...ke over for the biological heart, the Jarvik 2000 ...
Medicine Products: